[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"delirium\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:delirium":29},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,81,0,25,[9,43,75,119,139,164,191,219,251,278,300,324,352,373,397,422,438,454,487,506,530,564,591,617,650],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100643250","vr-based-cognitive-stimulation-games-for-delirium-prevention-100643250",false,"NCT07641153","VR-Based Cognitive Stimulation Games for Delirium Prevention","Virtual Reality-Based Cognitive Stimulation Games for Enhancing Attention and Preventing Delirium in Older Surgical Patients With Cognitive Impairment","Inclusion Criteria:\n\n* Men and women ≥65 years of age\n* Have a pre-existing diagnosis of cognitive impairment (Montreal Cognitive Assessment Score of 15-24)\n* Elective or emergency major surgery with the expectation of admission to the Intensive Care Unit following the surgery for three days following surgery\n\nExclusion Criteria:\n\n* Pre-existing Intubation and invasive ventilation;\n* history of severe mental illness;\n* admission for a drug overdose;\n* severe vertigo;\n* history of severe postoperative nausea and vomiting;\n* hearing and visual impairment;\n* preexisting severe dementia (Montreal Cognitive Assessment Score \\\u003C 15; and\n* active delirium at the time of screening for eligibility criteria.\n* Active suicidal ideation or behavior Screen failure after surgery\n* Prolonged intubation after surgery (more than 24 hours)","ALL","65 Years",{"count":20,"type":21},90,"ESTIMATED","INTERVENTIONAL",[24],"NA","This trial aims to evaluate the feasibility, safety, and acceptability of a virtual reality (VR)-based cognitive stimulation game to reduce postoperative delirium among older surgical patients at high risk due to pre-existing cognitive impairment.",[27,28,29],"Surgery","Delirium - Postoperative","Delirium","RECRUITING","2026-06-08",{"date":33,"type":34},"2026-06-11","ACTUAL",{"date":36,"type":34},"2026-04-24",{"date":38,"type":21},"2029-05-01",{"name":40,"class":41},"The Methodist Hospital Research Institute","OTHER",2,{"id":44,"slug":45,"hasResults":12,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":12,"sex":17,"minAge":51,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":22,"phases":54,"briefSummary":55,"conditions":56,"keywords":61,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":74},"100518226","ctsn-embolic-protection-trial-100518226","NCT06027788","CTSN Embolic Protection Trial","Embolic Protection in Patients Undergoing High-Risk Valve Surgery","EMPRO","Inclusion Criteria:\n\n* Age ≥ 60 years\n* Planned de novo or redo:\n\n  * Surgical aortic valve replacement SAVR ± ascending aortic repair (if circulatory arrest is not required) ± CABG\n  * Mitral valve replacement (MVR) ± CABG\n  * Mitral Valve Repair + CABG,\n  * Double\u002FTriple valve surgery ± CABG; Ross procedure These procedures can be done via a full or minimal-access sternotomy (using central aortic perfusion cannulae) with legally marketed valve(s), and can be done in combination with an left atrial appendage (LAA) closure\u002Fexcision or partial\u002Fcomplete Maze procedure.\n  * Valve sparing aortic root replacement (David procedure)\n  * Valve sparing aortic root replacement (David procedure)\n* No evidence of neurological impairment as defined by a NIHSS ≤1 and modified Rankin scale (mRS) ≤2 within 30 days prior to randomization\n* Ability to provide informed consent and comply with the protocol\n\nExclusion Criteria:\n\n* History of clinical stroke within 3 months prior to randomization\n* Cerebral and or aortic arch arteriography or interventions within 3 days of the planned procedure\n* Coronary catheterization within 3 days of index procedure, and the required repeat NIHSS score post-catheterization is worse than the screening\u002Fbaseline NIHSS score conducted prior to the catheterization\n* Active endocarditis at time of randomization with vegetation criteria\n* Clinical signs of cardiogenic shock or treatment with IV inotropic therapy prior to randomization\n* Participation in an interventional (drug or device) trial\n* Isolated mitral valve repair, isolated tricuspid valve repair or combined mitral valve repair and tricuspid valve repair\n* Anticipated requirement for prolonged mechanical ventilation greater than 48 hours after surgery in the opinion of the investigator\n* Planned concomitant carotid endarterectomy during index surgical procedure","60 Years",{"count":53,"type":21},842,[24],"This is a prospective, multi-center, randomized effectiveness trial of the CardioGard Embolic Protection Cannula in high-risk valve surgery patients.",[29,57,58,59,60],"Ischemic Stroke","Acute Kidney Injury","Heart Valve Disease","Coronary Artery Disease",[62,63,64],"Embolic Protection","Cardiac Surgery","CardioGard","2026-05-26",{"date":67,"type":34},"2026-05-29",{"date":69,"type":34},"2023-09-18",{"date":71,"type":21},"2027-04-01",{"name":73,"class":41},"Icahn School of Medicine at Mount Sinai",28,{"id":76,"slug":77,"hasResults":12,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":4,"eligibilityCriteria":81,"healthyVolunteers":12,"sex":17,"minAge":82,"maxAge":4,"enrollmentInfo":83,"targetDuration":4,"studyType":85,"phases":4,"briefSummary":86,"conditions":87,"keywords":92,"overallStatus":108,"whyStopped":4,"lastUpdateSubmitDate":109,"lastUpdatePostDateStruct":110,"startDateStruct":112,"completionDateStruct":114,"leadSponsor":116,"locationsCount":118},"100638143","prospective-observational-multimodal-neuromonitoring-during-high-risk-adult-surgery-100638143","NCT07577726","Prospective Observational Multimodal Neuromonitoring During High-Risk Adult Surgery","Prospective Observational Multimodal Neuromonitoring During High-Risk Adult Surgery: A Single-Center Cohort Study of Quantitative EEG, Noninvasive Intracranial Dynamics, and Perioperative Physiologic Correlates","Inclusion Criteria:\n\n* Age 18 years or older\n* Scheduled to undergo major spine surgery, liver transplantation, on-pump cardiac surgery, major vascular surgery, major thoracic surgery, major abdominal surgery, or neurosurgical craniotomy at UT Southwestern Medical Center\n* Able to provide informed consent (self or legally authorized representative when applicable)\n* Safe and feasible placement of SedLine and\u002For Brain4Care monitoring as determined by the clinical and research teams\n* Anticipated availability of perioperative clinical data needed for study analyses\n\nExclusion Criteria:\n\n* Age younger than 18 years\n* Prisoner status\n* Pregnancy\n* Unable to provide informed consent in English (consent documents available in English only)\n* Declining participation\n* Lack of subject or legally authorized representative consent when required\n* Clinical condition preventing safe or feasible placement of study monitors (e.g., incompatible surgical field location, significant facial or scalp injury, open wounds at intended sensor placement site)\n* Operative workflow or clinical urgency precluding reasonable completion of consent and monitor placement prior to start of surgery\n* Anticipated clinical data capture insufficient for meaningful analysis","18 Years",{"count":84,"type":21},300,"OBSERVATIONAL","This is a prospective observational cohort study of adult patients undergoing high-risk surgery at UT Southwestern Medical Center. The study acquires synchronized multimodal neuromonitoring data - including SedLine quantitative EEG (qEEG) extracted from standard-of-care clinical monitoring and, where deployed, Brain4Care (B4C) noninvasive intracranial dynamics data - and links these data to perioperative hemodynamic, medication, laboratory, procedural, and outcome variables. No alteration of routine clinical care occurs. The primary goal is to characterize associations between monitor-derived features and perioperative clinical variables, and to establish a multimodal dataset supporting future analyses of perioperative brain health in high-risk surgical populations.",[88,29,89,90,91],"Postoperative Cognitive Complications","Perioperative\u002FPostoperative Complications","Brain Injuries","Anesthesia",[93,94,95,96,97,98,99,100,101,102,103,104,105,106,107],"quantitative EEG","SedLine","Brain4Care","intracranial dynamics","cerebrovascular reactivity","perioperative neuromonitoring","postoperative delirium","perioperative brain health","cardiac surgery","liver transplantation","spine surgery","Moberg Clinical Platform","cerebral autoregulation","high-risk surgery","intraoperative monitoring","NOT_YET_RECRUITING","2026-05-04",{"date":111,"type":34},"2026-05-11",{"date":113,"type":21},"2026-07",{"date":115,"type":21},"2028-12",{"name":117,"class":41},"University of Texas Southwestern Medical Center",1,{"id":120,"slug":121,"hasResults":12,"nctId":122,"briefTitle":123,"officialTitle":124,"acronym":4,"eligibilityCriteria":125,"healthyVolunteers":12,"sex":17,"minAge":82,"maxAge":4,"enrollmentInfo":126,"targetDuration":4,"studyType":22,"phases":128,"briefSummary":129,"conditions":130,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":133,"lastUpdatePostDateStruct":134,"startDateStruct":135,"completionDateStruct":137,"leadSponsor":138,"locationsCount":118},"100571323","neurosteer-bedside-monitoring-system-100571323","NCT06718764","Neurosteer Bedside Monitoring System","Evaluating the Feasibility of Utilizing a Novel Brain Activity Monitor in the Neurosciences Intensive Care Unit","Inclusion Criteria:\n\n* Provision of signed and dated informed consent form from patient and\u002For LAR, including stated willingness to comply with all study procedures and availability for the duration of the study\n* Any assigned sex at birth, including individuals who are transgender or intersex\n* Age 18 years or older\n* Mechanically ventilated patients with an anticipated LOS \\>\u002F=48 hours on any sedative drips including propofol, midazolam, dexmedetomidine, fentanyl, dialudid, ketamine\n\nExclusion Criteria:\n\n* Has known hearing problems and usage of hearing aids\n* Has a rash on forehead\n* History of polysubstance abuse\n* Severe dementia\n* Anticipated Withdrawing Life-Sustaining Therapy (WLST) within the next 24-48 hours",{"count":127,"type":21},100,[24],"The purpose of this study is to evaluate the clinical utility of Neurosteer's brain monitoring platform for monitoring delirium, sedation, and agitation in intubated and sedated ICU patients. The research team will be conducting a single-site study. The research team will enroll 100 patients admitted to the NSICU. 50 of these patients will have Acute Neurological Injuries (ANI) and the other 50 will not have an ANI. All enrolled patients will receive the intervention, the Neurosteer brain monitoring device.\n\nThe study intervention consists of the use of Neurosteer's innovative single-channel EEG monitoring device to determine if there is a good correlation and agreement between their signals\u002Fparameters to RASS, CAM-ICU, and continuous EEG monitoring readings. The Neurosteer device will be attached to their forehead and readings will be collected for the duration of their NSICU stay. The research team will adapt the current physical methods of detecting the depth of anesthesia i.e. through the Richmond Agitation-Sedation Scale (RASS) \\& CAM-ICU, to auditory stimulation, which will be delivered through earphones with no physical contact, with the aim of achieving a high correlation between the methods. RASS and CAM-ICU will be collected hourly as standard of care and Neurosteer auditory stimulation will be done 3-4 times a day to coincide with RASS and 1-2 times a day to coincide with CAM-ICU. The research team will correlate collected hourly RASS and CAM-ICU assessments with Neurosteer derived signals and parameters.",[29,131,132],"Sedation","Agitation","2026-04-28",{"date":109,"type":34},{"date":136,"type":34},"2024-07-08",{"date":113,"type":21},{"name":73,"class":41},{"id":140,"slug":141,"hasResults":12,"nctId":142,"briefTitle":143,"officialTitle":144,"acronym":145,"eligibilityCriteria":146,"healthyVolunteers":12,"sex":17,"minAge":147,"maxAge":4,"enrollmentInfo":148,"targetDuration":4,"studyType":22,"phases":150,"briefSummary":151,"conditions":152,"keywords":154,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":133,"lastUpdatePostDateStruct":157,"startDateStruct":158,"completionDateStruct":160,"leadSponsor":162,"locationsCount":42},"100363070","nocturnal-hypoxia-in-geriatric-patients-after-hip-fracture-100363070","NCT04007432","Nocturnal Hypoxia in Geriatric Patients After Hip Fracture","Nocturnal Hypoxia in Patients Hospitalized in Orthogeriatrics After Hip Fracture","HIPOX","Inclusion Criteria:\n\n* age over 70 years old,\n* hospitalized in orthogeriatrics for hip fracture surgery\n* information about the study and expression of non opposition\n* Expected hospital stay of 5 nights or more\n\nExclusion Criteria:\n\n* patient under guardianship,\n* any other type of fracture associated,\n* oxymetry recording not possible (behavioral disorders, night stirring,...)","70 Years",{"count":149,"type":21},70,[24],"Delirium is a common complication following hip fracture surgery (HFS) in older people. Postoperative hypoxia has also been associated with delirium, but not specifically in geriatric patients. The aim of the study is to demonstrate that post-operative hypoxia is associated with in-hospital complications in patients with HFS.",[29,153],"Hypoxia",[155,156],"nocturnal hypoxia","delirum developpement",{"date":109,"type":34},{"date":159,"type":34},"2020-11-05",{"date":161,"type":21},"2028-11-05",{"name":163,"class":41},"Assistance Publique - Hôpitaux de Paris",{"id":165,"slug":166,"hasResults":12,"nctId":167,"briefTitle":168,"officialTitle":169,"acronym":170,"eligibilityCriteria":171,"healthyVolunteers":172,"sex":17,"minAge":51,"maxAge":4,"enrollmentInfo":173,"targetDuration":4,"studyType":22,"phases":175,"briefSummary":176,"conditions":177,"keywords":178,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":183,"startDateStruct":185,"completionDateStruct":187,"leadSponsor":189,"locationsCount":118},"100636250","computer-assisted-cognitive-stimulation-treatment-for-delirium-100636250","NCT07563244","Computer-assisted Cognitive Stimulation Treatment for Delirium","Clinical, Demographic and Genetic Factors Associated With Response to Computer-assisted Cognitive Stimulation Treatment as Part of Non-pharmacological Care in Patients With Delirium. Feasibility Study.","Delitract","Inclusion Criteria:\n\n* All patients aged 60 years or over who are admitted to the subacute care center between 15 February and 15 October 2026 and who sign the informed consent (the patient and their family or legal guardians if the patient's cognitive condition prevents them from giving consent themselves)\n\nExclusion Criteria:\n\n* Patients who, at the time of admission, meet the criteria for palliative end-of-life care.\n* Individuals under 60 years of age, to ensure sample homogeneity and reduce confounding factors.\n* Individuals with severe visual or hearing impairment or aphasia, due to the difficulty of carrying out the cognitive intervention.\n* Serious communication difficulties due to language.",true,{"count":174,"type":21},60,[24],"The objectives of our study are to determine whether people with delirium in a subacute care unit improve after one week with non-pharmacological therapies based on improving sleep schedules, mobility, and cognitive stimulation (such as memory, attention, orientation, among others), and to compare two groups of people who will receive slightly different therapies.\n\nWe will try to determine whether individual characteristics (such as diagnosed diseases, blood test results or genetics, gender, age, educational level, among others) influence the onset of an episode of delirium, its severity and its response to treatment.\n\nParticipants with delirium will be divided into two groups that will receive:\n\n* The non-pharmacological treatment described\n* One group will also receive a specific cognitive intervention from an occupational therapist, using a computer programme on a tablet, twice a day for one week.\n\nAfter one week, the presence and severity of delirium will be reassessed.",[29],[29,179,180,181,182],"Older adults","Dementia","Subacute care","Cognitive training",{"date":184,"type":34},"2026-05-01",{"date":186,"type":34},"2026-02-16",{"date":188,"type":21},"2027-02-16",{"name":190,"class":41},"Institut Investigacio Sanitaria Pere Virgili",{"id":192,"slug":193,"hasResults":12,"nctId":194,"briefTitle":195,"officialTitle":196,"acronym":197,"eligibilityCriteria":198,"healthyVolunteers":12,"sex":17,"minAge":51,"maxAge":4,"enrollmentInfo":199,"targetDuration":4,"studyType":22,"phases":201,"briefSummary":203,"conditions":204,"keywords":206,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":211,"startDateStruct":213,"completionDateStruct":215,"leadSponsor":217,"locationsCount":118},"100590582","phase-3-mitigating-delirium-with-fluvoxamine-treatment-for-non-cardiac-surgery-100590582","NCT06969287","Mitigating Delirium With Fluvoxamine Treatment for Non-Cardiac Surgery","Mitigating Delirium With Fluvoxamine Treatment for Non-Cardiac Surgery (MD FluNCS)","MD FluNCS","Inclusion Criteria:\n\n* English-speaking\n* elective non-cardiac or non-intracranial surgery requiring at least a 2-day hospital length of stay\n\nExclusion Criteria:\n\n* Received investigational drug within the last 7 weeks\n* lack of capacity to provide informed consent\n* prior known intolerance or allergy to SSRIs or fluvoxamine\n* planned postoperative ventilation\n* drug or alcohol dependence\n* preoperative use of non-NSAID medications with drug-drug interactions of Class X (Avoid Combination) or D (Consider Therapy Modification)\n* risk of serotonin syndrome (St John's Wort, SSRIs, or TCA)",{"count":200,"type":21},46,[202],"PHASE3","The investigation will establish biological plausibility and infrastructure required for a multisite clinical trial evaluating the re-purposing of fluvoxamine to mitigate postoperative delirium risk in geriatric patients undergoing non-cardiac non-intracranial surgery.",[29,205],"Surgery-Complications",[207,208,209,210],"delirium","geriatric","surgery","fluvoxamine",{"date":212,"type":34},"2026-04-29",{"date":214,"type":34},"2026-04-06",{"date":216,"type":21},"2028-04-01",{"name":218,"class":41},"Washington University School of Medicine",{"id":220,"slug":221,"hasResults":12,"nctId":222,"briefTitle":223,"officialTitle":224,"acronym":225,"eligibilityCriteria":226,"healthyVolunteers":12,"sex":17,"minAge":82,"maxAge":227,"enrollmentInfo":228,"targetDuration":4,"studyType":22,"phases":230,"briefSummary":231,"conditions":232,"keywords":235,"overallStatus":108,"whyStopped":4,"lastUpdateSubmitDate":242,"lastUpdatePostDateStruct":243,"startDateStruct":245,"completionDateStruct":247,"leadSponsor":249,"locationsCount":4},"100634669","respiratory-physiotherapy-and-pmr-after-cardiac-surgery-100634669","NCT07542691","Respiratory Physiotherapy and PMR After Cardiac Surgery","Effect of Respiratory Physiotherapy and Progressive Muscle Relaxation Exercises on Dyspnea, Anxiety, Hemodynamic Status and Delirium Symptoms After Cardiac Surgery: A Randomized Controlled Trial","RESP-PMR","Inclusion Criteria:\n\n* Patients aged 18-80 years who have undergone cardiac surgery\n* Hemodynamically stable patients\n* Patients able to cooperate and follow instructions\n* Patients with postoperative dyspnea\n* Patients who provide written informed consent\n\nExclusion Criteria:\n\n* Patients with severe cognitive impairment or inability to cooperate\n* Patients with neurological or psychiatric disorders affecting participation\n* Patients requiring mechanical ventilation for prolonged periods\n* Patients with unstable hemodynamic status\n* Patients with contraindications to respiratory physiotherapy or exercise\n* Patients who refuse to participate","80 Years",{"count":229,"type":21},116,[24],"This study aims to evaluate the effects of respiratory physiotherapy combined with progressive muscle relaxation exercises on dyspnea, anxiety, hemodynamic status, and delirium symptoms in patients after cardiac surgery. This randomized controlled trial will include 116 patients who will be randomly assigned to an intervention group or a control group. The intervention group will receive respiratory physiotherapy and progressive muscle relaxation exercises in addition to routine postoperative care for 30 minutes per day over three consecutive days, while the control group will receive routine care only. Outcome measures will include dyspnea assessed by the Modified Borg Scale, anxiety assessed by the State-Trait Anxiety Inventory, hemodynamic parameters obtained from vital signs, and delirium symptoms assessed using the Nursing Delirium Screening Scale. It is hypothesized that the combined intervention will reduce dyspnea and anxiety levels, improve hemodynamic stability, and decrease delirium symptoms. The findings are expected to contribute to improved postoperative recovery and reduced complication risks following cardiac surgery.",[63,233,234,29],"Dyspnea","Anxiety",[236,237,238,239,240,241],"Respiratory Physiotherapy","Progressive Muscle Relaxation","Cardiac Rehabilitation","Postoperative Care","Intensive Care Unit","Hemodynamic Parameters","2026-04-17",{"date":244,"type":34},"2026-04-21",{"date":246,"type":21},"2026-05",{"date":248,"type":21},"2026-06",{"name":250,"class":41},"Istanbul Aydın University",{"id":252,"slug":253,"hasResults":12,"nctId":254,"briefTitle":255,"officialTitle":256,"acronym":4,"eligibilityCriteria":257,"healthyVolunteers":12,"sex":17,"minAge":258,"maxAge":4,"enrollmentInfo":259,"targetDuration":4,"studyType":22,"phases":261,"briefSummary":262,"conditions":263,"keywords":265,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":242,"lastUpdatePostDateStruct":270,"startDateStruct":272,"completionDateStruct":274,"leadSponsor":276,"locationsCount":118},"100612784","tavns-for-delirium-100612784","NCT07258082","TaVNS for Delirium","Transauricular Vagus Nerve Stimulation (taVNS) for Delirium","Inclusion Criteria:\n\n* Stony Brook University Hospital inpatient, Age \\> 22\n* Right- handed\n* Screen positive for delirium on ICDSC instrument\n\nExclusion Criteria:\n\n* Severe neurologic disability including severe traumatic brain injury, severe permanent cognitive impairment\n* Pacemaker present\n* Implanted VNS stimulator present\n* Personal history of epilepsy\n* Facial or ear pain or trauma\n* Recent history of substance abuse\n* Any other medical condition that, in the judgment of the investigator, makes participation in the study unsafe.\n* Weight \\\u003C 40kg\n* Pregnant females\n* Intubated patient","22 Years",{"count":260,"type":21},10,[24],"The goal of this clinical trial is to test whether a non-invasive device called transauricular vagus nerve stimulation (taVNS) is safe, practical, and potentially helpful for patients in the hospital who develop delirium. Delirium is a state of confusion that often happens to people in the hospital who are sick or hurt. It can cause agitation, trouble paying attention and difficulty understanding what is happening. Delirium may slow overall recovery.\n\nThis study will focus on feasibility and safety. Researchers want to learn whether taVNS can be given safely to critically-ill patients, whether patients and staff can tolerate the treatments, and whether the device produces measurable changes in brain activity and brain oxygen levels.\n\nThe main questions this study aims to answer are:\n\n* Is it possible to deliver taVNS safely and consistently to patients in the ICU who have delirium?\n* Do patients tolerate the device without significant side effects or complications?\n* Does taVNS cause short-term changes in brain signals and oxygen levels that may suggest effects on brain function? This is an early feasibility study and there is no randomization or placebo group. All patients enrolled will receive taVNS in addition to their usual hospital care for delirium.\n\nWhat participants will do:\n\n* Be identified by their hospital care team and have a confirmed diagnosis of delirium.\n* Provide consent (or have a legally authorized representative provide consent if the patient cannot.)\n* Undergo brief assessments of thinking and attention (for example, the ICDSC test.)\n* Receive taVNS treatment using a small clip electrode placed on the ear.\n\n  * The device sends gentle electrical pulses to the nerve in the ear.\n  * Each session lasts about 30 minutes, given twice per day (morning and evening, with at least 6 hours between sessions).\n  * Treatment can continue for up to 7 days while the patient is in the ICU.\n* Be monitored during and after each session. The study team will check vital signs, examine the ear for irritation, and ask about any discomfort.\n* On the first day, researchers will also record brain signals (EEG) and brain oxygen levels before and during stimulation using FDA-approved hospital monitoring devices.\n\nPossible risks and discomforts:\n\n* Mild side effects are possible, such as tingling, a tickling or pricking feeling in the ear, or temporary skin redness where the clip is placed.\n* Serious side effects are not expected, but all patients will be closely monitored during and after each session to ensure safety.\n\nPossible benefits:\n\n• Patients may or may not experience personal benefit. The main benefit is helping researchers learn whether this treatment approach is safe and practical. In the future, taVNS could potentially become a new tool to help treat or prevent delirium in hospitalized patients.\n\nStudy size and duration:\n\n* The study will enroll a limited number of ICU patients with delirium at Stony Brook University Hospital.\n* Patients may take part for up to 7 days while hospitalized.\n\nWho can join:\n\n* Right-handed, adult patients in the ICU who are diagnosed with delirium.\n* People with certain medical conditions (such as brain bleeds, new strokes, pacemakers or other contraindications) may not be able to participate, for safety reasons.",[264,29],"Delirium Treatment",[207,266,267,268,269],"tavns","transauricular vagus nerve stimulation","vagus nerve stimulation","transcutaneous vagus nerve stimulation",{"date":271,"type":34},"2026-04-22",{"date":273,"type":34},"2025-09-26",{"date":275,"type":21},"2028-10",{"name":277,"class":41},"Stony Brook University",{"id":279,"slug":280,"hasResults":12,"nctId":281,"briefTitle":282,"officialTitle":283,"acronym":284,"eligibilityCriteria":285,"healthyVolunteers":12,"sex":17,"minAge":286,"maxAge":4,"enrollmentInfo":287,"targetDuration":4,"studyType":22,"phases":289,"briefSummary":290,"conditions":291,"keywords":4,"overallStatus":108,"whyStopped":4,"lastUpdateSubmitDate":292,"lastUpdatePostDateStruct":293,"startDateStruct":294,"completionDateStruct":296,"leadSponsor":298,"locationsCount":4},"100634287","eeg-tms-for-postoperative-delirium-after-cardiac-surgery-100634287","NCT07537725","EEG-TMS for Postoperative Delirium After Cardiac Surgery","Transcranial Magnetic Stimulation for Postoperative Delirium After Cardiac Surgery: A Prospective, Single-Center, Randomized Double-Blind Controlled Study","RECOVER-C","Inclusion Criteria:\n\n* Aged 50 years or older;\n* undergoing cardiac surgery with cardiopulmonary bypass (coronary artery bypass grafting, aortic valve replacement, mitral valve surgery, or combined procedures);\n* positive assessment by CAM-ICU postoperatively.\n\nExclusion Criteria:\n\n* Chronic antipsychotic treatment;\n* Receipt of antipsychotic medication before enrollment;\n* Patients with permanent loss of autonomy;\n* Not suitable for delirium assessment: including language disorder, deafness, blindness, aphasia, or coma;\n* Withdrawal of treatment or brain death;\n* Known pregnancy or breastfeeding;\n* Unable to provide consent according to national regulations;\n* Patients involuntarily hospitalized by regulatory authorities (compulsory measures);\n* Alcohol-induced delirium \u002F delirium tremens;\n* Contraindications to transcranial magnetic stimulation, including intracranial or cervical metal implants, history of brain surgery, history of epilepsy, cardiac pacemaker or implantable cardioverter-defibrillator, cochlear implant, known intracranial space-occupying lesions, cardiac pacemaker implantation, recent stroke (\\\u003C3 months);\n* Acute infectious diseases;\n* Preoperative severe hemodynamic instability (e.g., requiring intra-aortic balloon pump or extracorporeal membrane oxygenation support).","50 Years",{"count":288,"type":21},144,[24],"This is a prospective, single-center, randomized, double-blind, sham-controlled trial evaluating the safety and efficacy of transcranial magnetic stimulation (TMS) for the treatment of postoperative delirium in patients undergoing cardiac surgery with extracorporeal circulation. Eligible patients aged 50 years or older who develop delirium after surgery, as assessed by the CAM-ICU, will be randomized to receive either active TMS or sham stimulation. The intervention consists of three daily cycles of intermittent and continuous theta burst stimulation over five days. The primary outcome is the duration of delirium within the five-day intervention period. Secondary outcomes include delirium severity, time to successful discharge, and survival at 30 and 90 days. A total of 144 participants will be enrolled.",[29],"2026-04-13",{"date":242,"type":34},{"date":295,"type":21},"2026-04-27",{"date":297,"type":21},"2027-03-31",{"name":299,"class":41},"RenJi Hospital",{"id":301,"slug":302,"hasResults":12,"nctId":303,"briefTitle":304,"officialTitle":305,"acronym":306,"eligibilityCriteria":307,"healthyVolunteers":12,"sex":17,"minAge":82,"maxAge":4,"enrollmentInfo":308,"targetDuration":4,"studyType":22,"phases":310,"briefSummary":312,"conditions":313,"keywords":4,"overallStatus":108,"whyStopped":4,"lastUpdateSubmitDate":292,"lastUpdatePostDateStruct":316,"startDateStruct":318,"completionDateStruct":320,"leadSponsor":322,"locationsCount":4},"100579421","early-phase-1-reducing-days-delirious-with-dexmedetomidine-as-part-of-an-intensive-care-unit-sleep-promotion-bundle-100579421","NCT06824077","Reducing Days DELirious With DEXmedetomidine as Part of an Intensive Care Unit Sleep Promotion Bundle","A Randomised, Placebo Controlled Clinical Trial of Dexmedetomidine as Part of a Sleep Promotion Bundle to Improve Sleep in Intensive Care","DELDEX","Inclusion Criteria:\n\n* Adult patient aged 18 years old or over admitted to the ICU\n* Anticipated to stay in the ICU for another 48 hours after the first sleep recording\n* Mechanically ventilated or on high flow oxygen (Optiflow)\n* Hemodynamically stable\n* Conscious, non-sedated patient with capacity to complete a self-reported sleep assessment\\*\n\nExclusion Criteria:\n\n* Contraindication to dexmedetomidine (including but not limited to allergy and bradycardia \\[heart rate \\\u003C 50 beats per minute\\])\n* Currently receiving dexmedetomidine or other alpha-2 agonists (e.g., clonidine)\n* Patients with structural neurological disease (e.g., stroke or tumor or traumatic brain injury) or degenerative neurologic disease (e.g., Parkinson's disease or dementia) and GCS \\\u003C 14\n* Patients with second- or third-degree heart block (unless pacemaker implanted)\n* Patients with clinically significant hepatic or renal disease\n* Patients with limitations in therapy or actively being palliated\n* Patients with primary psychiatric disorder (e.g., new diagnosis of or uncontrolled schizophrenia, severe depression)\n* Patients experiencing substance intoxication or withdrawal (e.g., severely agitated delirium)\n* Patients participating in other studies involving the use of pharmacologically active substances\n* Treating clinician believes study participation is not in the patient's best interest\n* Pregnancy or breastfeeding",{"count":309,"type":21},50,[311],"EARLY_PHASE1","Patients frequently experience problems with sleep while admitted to the ICU. Good sleep is important in ensuring that your immune system responds properly to infection, for your heart to function optimally, and to support normal brain function such as memory.\n\nTo address sleep problems in the ICU, a bundle of interventions to support more normal sleep are provided. These bundles consist of medications such as sedatives and environmental changes such as less frequent times being assessed overnight and noise reduction strategies. Although medications can make patients appear to be sleeping, most medications do not provide patients with restful sleep. More research is needed on medications that better mimick restful sleep. One such medication is dexmedetomidine. When formally measured dexmedetomidine can make sleep appear more like a patient sleeping at home as compared to the hospital.\n\nThe purpose of this study is to test whether giving a patient in the intensive care unit dexmedetomidine helps have a more restful sleep and possibly be more alert and\u002For interactive the next day.\n\nTo see if dexmedetomidine improves sleep, the investigators will compare the quality of sleep of two different groups of participants: one group that receives dexmedetomidine at night for 2 nights in a row and another group that does not. How well one sleeps will be measured, in either group, will be assessed by a portable sleep machine that is attached by several stickers.\n\nThis study is called a pilot or feasibility study. A pilot study assesses how easy it is to recruit patients, whether the sleep machine is tolerated, and amount of time sleep is measured.\n\nIt is anticipated that about 50 people will take part in this study. This study should take approximately 2 years to complete, and the results should be known in about 1-2 years thereafter.",[314,29,315],"Sleep","ICU Hospitalization",{"date":317,"type":34},"2026-04-15",{"date":319,"type":21},"2026-08-01",{"date":321,"type":21},"2027-03-01",{"name":323,"class":41},"University of Alberta",{"id":325,"slug":326,"hasResults":12,"nctId":327,"briefTitle":328,"officialTitle":329,"acronym":330,"eligibilityCriteria":331,"healthyVolunteers":12,"sex":17,"minAge":286,"maxAge":4,"enrollmentInfo":332,"targetDuration":4,"studyType":85,"phases":4,"briefSummary":334,"conditions":335,"keywords":338,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":343,"lastUpdatePostDateStruct":344,"startDateStruct":346,"completionDateStruct":348,"leadSponsor":350,"locationsCount":118},"100529339","automating-delirium-severity-in-the-icu-100529339","NCT06172491","Automating Delirium Severity in the ICU","Harnessing the Power of Technology to Transform Delirium Severity Measurement in the ICU","ADS-ICU","Inclusion Criteria: • Age \\>50;\n\n* Estimated length of stay \\>24 hours in ICU; and\n* Are not admitted for acute alcohol intoxication, drug (prescribed or illicit) overdose or withdrawal.\n\nExclusion Criteria:\n\n* Admitted for acute alcohol intoxication, drug (prescribed or illicit) overdose or withdrawal.\n* Admitted for acute neuronal injury\n* Unable to communicate with research team due to sensory deficits (aphasic, blind, deaf) or language (does not speak English)",{"count":333,"type":21},400,"The goal of this observational study is to develop a passive digital marker (PDM) for delirium severity and examine its performance in comparison to validated delirium severity tools in ICU patients \\>50 years of age.\n\nThe main questions it aims to answer are:\n\n* Is the trained convolutional neural network able to reliably measure delirium severity.\n* Is the Passive Digital Marker able to accurately measure delirium severity\n* Is the Passive Digital Marker acceptable and usable by frontline ICU nurse clinicians, patients, and their identified proxies (i.e., caregivers).\n\nParticipants will:\n\n* Study participation involves a video camera recording you 24 hours per day while you are a patient in the Intensive Care Unit (ICU).\n* Study staff will visit you 4 times each day you are in the ICU. You will be asked questions each time they visit to train the digital marker and see differences between assessments and camera data.",[336,337,29],"Intensive Care Unit Delirium","Encephalopathy",[29,339,340,341,342],"Severity","Digital marker","Computer Vision","Artificial Intelligence","2026-04-02",{"date":345,"type":34},"2026-04-08",{"date":347,"type":34},"2023-01-15",{"date":349,"type":21},"2028-05-31",{"name":351,"class":41},"Mayo Clinic",{"id":353,"slug":354,"hasResults":12,"nctId":355,"briefTitle":356,"officialTitle":357,"acronym":358,"eligibilityCriteria":359,"healthyVolunteers":12,"sex":17,"minAge":82,"maxAge":227,"enrollmentInfo":360,"targetDuration":4,"studyType":22,"phases":361,"briefSummary":362,"conditions":363,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":364,"lastUpdatePostDateStruct":365,"startDateStruct":367,"completionDateStruct":369,"leadSponsor":371,"locationsCount":118},"100619734","fecal-microbiota-transplantation-for-the-treatment-of-icu-delirium-100619734","NCT07348471","Fecal Microbiota Transplantation for the Treatment of ICU Delirium","Fecal Microbiota Transplantation for the Treatment of ICU Delirium: An Investigator-Initiated, Prospective, Two-Arm, Single-Center, Non-Blinded, Randomized Controlled Trial","FMTID","Inclusion Criteria:\n\n* 1\\. Age ≥ 18 years old, no ethnic or gender restrictions;\n* 2\\. CAM-ICU-positive delirium;\n* 3\\. Expected ICU stay ≥ 5 days after inclusion in the study;\n* 4\\. Signed written informed consent.\n\nExclusion Criteria:\n\n* 1\\. Routine administration of antipsychotic medications: Conventional antipsychotic therapy refers to the daily ingestion or application of any sustained-release formulation (in any dosage form) of antipsychotic drugs with the ATC code N05A (in any form), including the following agents:\n\n  1. Typical antipsychotics: Chlorprothixene, Flupentixol, Haloperidol, Levomepromazine, Loxapine, Melperone, Perphenazine, Pericyazine, Pimozide, Prochlorperazine, Zuclopenthixol, Pimavanserin, Sulpiride.\n  2. Atypical antipsychotics: Amisulpride, Aripiprazole, Asenapine, Clozapine, Lurasidone, Olanzapine, Paliperidone, Quetiapine, Risperidone, Sertindole, Ziprasidone. However, the non-habitual administration of antipsychotic medications in the general ward prior to the patient's ICU admission (e.g., for the management of delirium) is deemed acceptable. Nevertheless, antipsychotic therapy should be discontinued upon the patient's ICU admission.\n* 2\\. Severe systemic infection in the early stage of resuscitation, hemodynamic instability or insufficient tissue perfusion, and severe imbalance of water, electrolyte and acid-base.\n* 3\\. Patients with a high risk of death within 5 days as judged by the clinician, or those whose treatment decisions are restricted.\n* 4\\. Active major gastrointestinal bleeding, perforation, or other severe damage to the intestinal barrier.\n* 5\\. Patients who cannot tolerate 50% of their caloric requirements through enteral nutrition due to severe diarrhea, significant fibrotic intestinal stenosis, severe gastrointestinal bleeding, or high-flow enteric fistula.\n* 6\\. Planned or recent abdominal surgery (within 14 days).\n* 7\\. Currently diagnosed with fulminant colitis or toxic megacolon.\n* 8\\. Recently received high-risk immunosuppressive or cytotoxic drug treatment: such as rituximab, doxorubicin, or medium to high-dose corticosteroids (20 mg\u002Fd prednisone or higher) for more than 4 weeks.\n* 9\\. Pregnant or lactating women.\n* 10\\. Participated in other clinical trials as a subject within the past 3 months or at the time of enrollment.\n* 11\\. Delirium assessment non applicable: this includes language barriers (patients with foreign language where delirium assessment cannot be confidently performed by the site staff), patients who are deaf, blind or aphasic. Comatose patients are not applicable for delirium assessment. Coma is defined by the following levels of consciousness: RASS -4 to -5. Further, RASS -3 may be considered as coma if this is the judgement of the treating physician. If a patient's coma is considered related to administration of sedative agents, an effort should be made to reduce or terminate the sedative treatment, according to the clinician's discretion.\n* 12\\. Doubtful validity of informed consent: subjects with mental illness, intellectual disability, poor motivation, or other factors that limit the validity of informed consent for participation in this study.",{"count":174,"type":21},[24],"Delirium in the intensive care unit (ICU) is a prevalent and serious neurological complication among critically ill patients, with large multicenter studies reporting an incidence of 30% to 80%, particularly in those requiring mechanical ventilation. Delirium is not only associated with prolonged ICU and hospital stays but also with increased morbidity and mortality. Notably, up to 40% of survivors suffer from persistent cognitive dysfunction that may last for months or even years. Despite current standard pharmacological interventions-such as haloperidol and second-generation antipsychotics-failing to demonstrate significant clinical benefit in phase III trials, non-pharmacological strategies remain challenging to implement due to environmental and operational constraints within the ICU. This unmet clinical need underscores the imperative to develop novel, effective therapeutic approaches.\n\nEmerging evidence suggests that ICU-acquired gut microbiota dysbiosis plays a pivotal role in the pathogenesis of delirium. Dysbiosis can compromise intestinal barrier integrity, promoting systemic inflammation and increasing susceptibility to various forms of delirium, including acute illness-related and postoperative types. These effects are likely mediated through the \"gut-microbiota-brain axis,\" which may represent a central mechanism underlying neurocognitive dysfunction in critical illness.\n\nPreclinical studies have demonstrated that fecal microbiota transplantation (FMT) can restore microbial balance and exert beneficial effects on neurological function. FMT has shown promise in ameliorating cognitive deficits in models of Alzheimer's disease, chronic cerebral hypoperfusion, traumatic brain injury, and chronic unpredictable mild stress (CUMS). Clinically, FMT has been associated with cognitive improvement in patients with dementia, recurrent Clostridioides difficile infection, and sepsis-associated encephalopathy. With expanding applications in both gastrointestinal and extraintestinal disorders, FMT has emerged as a transformative therapeutic modality, supported by robust short- and long-term safety and efficacy data.\n\nThis study aims to evaluate whether FMT can alleviate delirium severity, correct gut microbiota dysbiosis at 0, 72, and 120 hours post-enrollment, attenuate intestinal barrier dysfunction, reduce systemic inflammation and disease severity, shorten ICU length of stay, and lower rates of ICU mortality, in-hospital mortality, and 28-day all-cause mortality-ultimately positioning FMT as a potential breakthrough intervention for ICU delirium.",[29],"2026-04-01",{"date":366,"type":34},"2026-04-03",{"date":368,"type":34},"2026-03-18",{"date":370,"type":21},"2028-12-30",{"name":372,"class":41},"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology",{"id":374,"slug":375,"hasResults":12,"nctId":376,"briefTitle":377,"officialTitle":377,"acronym":378,"eligibilityCriteria":379,"healthyVolunteers":12,"sex":17,"minAge":51,"maxAge":4,"enrollmentInfo":380,"targetDuration":4,"studyType":22,"phases":382,"briefSummary":383,"conditions":384,"keywords":385,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":389,"lastUpdatePostDateStruct":390,"startDateStruct":391,"completionDateStruct":393,"leadSponsor":395,"locationsCount":118},"100603548","delirium-in-neurodegenerative-disease-patients-a-music-therapy-intervention-for-hospital-care-100603548","NCT07137949","Delirium in Neurodegenerative Disease Patients: A Music Therapy Intervention for Hospital Care","DyNamic","Inclusion Criteria:\n\n* Admitted as inpatient to Boston Medical Center.\n* Cognitive impairment or neurodegenerative diseases as defined by either:\n\n  * Diagnosis of Parkinson's Disease, Dementia with Lewy Bodies (ICD-10 G20 and G31.83 respectively), Alzheimer's Disease-related dementias (ICD-10 6D80), vascular dementia (F01), or other cognitive impairment (R41) on active problem list or past medical history\n  * \"Cognitive impairment\" on active problem list or past medical history\n  * Documentation elsewhere in the electronic medical record (e.g. notes) of any of these conditions\n* Participants with cognitive impairment will be included. If unable to consent, legally authorized representative (LAR) based on HRP-013-SOP-LARs, Children, and Guardians will be contacted to consent.\n* Spanish speaking participants will be included. Screening and informed consent procedures will be conducted using a certified medical interpreter. All intervention sessions and study team interactions will be conducted using these interpreter services.\n* Patients admitted to an intensive care unit will be included as long as they are not receiving continuous intravenous sedative medications. Potential participants in the intensive care unit setting will be discussed with a PI\u002Fco-I to ensure participation is appropriate on a case-by-case basis. The PI\u002FCo-I will confirm with the treating physician that there are no reasons as to why the potential participant should not be enrolled in the study.\n\nExclusion Criteria:\n\n* Admitted to observation status (as these patients would not be expected to remain inpatient long enough to undergo the MT intervention)\n* Patients who will be discharged within 24 hours of eligibility based on discussion with primary admitting team\n* Self-reported history of musicogenic seizures\n* Hearing loss: unable to hear a recorded sound \\\u003C70 decibels (dB)\n* Dislike of music: Barcelona Music Reward Questionnaire score of \\\u003C40\n* Patients who are currently prisoners\n* Patients in the intensive care unit receiving continuous intravenous sedative medication\n* Pregnant women",{"count":381,"type":21},30,[24],"In this pilot study a new kind of music therapy will be created and tested to help prevent confusion, called delirium, that can happen in the hospital. This can affect people with brain diseases like Alzheimer's disease and Parkinson's disease.\n\nEach of the anticipated 30 participants will have up to five music therapy sessions. The sessions will be made just for them and may include live music, playing instruments, or listening to recorded music. Surveys will be used to learn how easy the therapy is to do in the hospital and what people think about how helpful the sessions may be for future patients.",[29],[386,387,388],"Music therapy","Hospital acquired delirium","Neurodegenerative disease patients","2026-03-31",{"date":364,"type":34},{"date":392,"type":34},"2026-03-11",{"date":394,"type":21},"2026-12",{"name":396,"class":41},"Boston Medical Center",{"id":398,"slug":399,"hasResults":12,"nctId":400,"briefTitle":401,"officialTitle":401,"acronym":4,"eligibilityCriteria":402,"healthyVolunteers":12,"sex":17,"minAge":82,"maxAge":4,"enrollmentInfo":403,"targetDuration":4,"studyType":85,"phases":4,"briefSummary":405,"conditions":406,"keywords":407,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":414,"lastUpdatePostDateStruct":415,"startDateStruct":416,"completionDateStruct":418,"leadSponsor":420,"locationsCount":118},"100516686","exploring-of-serum-biomarkers-of-delirium-after-cardiovascular-surgery-100516686","NCT06007755","Exploring of Serum Biomarkers of Delirium After Cardiovascular Surgery","Inclusion Criteria:\n\npatients who receive cardiovascular surgery\n\n* Patients participated voluntarily and signed informed consent\n\nExclusion Criteria:\n\n* past medical history of neurological and psychiatric diseases; severe visual or hearing impairment;",{"count":404,"type":21},113,"The incidence of postoperative delirium in patients after cardiovascular surgery is very high, which seriously affects the short-term and long-term prognosis of patients, but its mechanism is not clear. Recent studies have found that lactic acid participates in the process of sepsis by inducing histone lactatation in macrophages. histone H3 lysine 18 lactylation (H3K18la) is significantly associated with the severity of disease and inflammatory response. Inflammation plays an important role in postoperative delirium. We therefore hypothesized that macrophage H3K18la also plays a role in postoperative delirium. At the same time, the latest literature shows that the early markers of Alzheimer's disease (AD), such as Aβ, exosomes and phosphorylated tau, etc. \\[5\\], can also be detected in the serum of AD patients. Given the obvious correlation between Alzheimer's disease and postoperative delirium \\[6\\], we hypothesized that serum biomarkers of AD could also be used as serum biomarkers for postoperative delirium.\n\nThe objectives of this study were to investigate the correlation between H3K18 in serum monocytes and postoperative delirium and its severity in patients undergoing cardiovascular surgery. Meanwhile, we also detect the serum levels of biomarkers of AD, such as Aβ, tau and exosomes etc., in patients undergoing major cardiac surgery. We aim to find the serum biomarkers of delirium after major cardiac surgery, so as to provide a more convenient diagnostic basis for the prevention of postoperative delirium.",[29],[207,408,409,410,411,412,413],"biomarker","cardiovascular surgery","H3K18la","exosome","phospho-tau","Aβ","2026-03-30",{"date":366,"type":34},{"date":417,"type":34},"2023-09-01",{"date":419,"type":21},"2027-12",{"name":421,"class":41},"Huazhong University of Science and Technology",{"id":423,"slug":424,"hasResults":12,"nctId":425,"briefTitle":426,"officialTitle":427,"acronym":4,"eligibilityCriteria":428,"healthyVolunteers":12,"sex":17,"minAge":82,"maxAge":4,"enrollmentInfo":429,"targetDuration":4,"studyType":85,"phases":4,"briefSummary":431,"conditions":432,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":414,"lastUpdatePostDateStruct":433,"startDateStruct":434,"completionDateStruct":436,"leadSponsor":437,"locationsCount":118},"100426404","perioperative-eeg-monitoring-and-postoperative-delirium-in-patients-undergoing-cardiovascular-surgery-100426404","NCT04832568","Perioperative EEG-Monitoring and Postoperative Delirium in Patients Undergoing Cardiovascular Surgery","Perioperative EEG-Monitoring and Postoperative Delirium in Patients Undergoing Cardiovascular Surgery: a Prospective Observational Study","Inclusion Criteria:\n\n1. age of at least 18 years\n2. normal cognitive function at the time of enrollment evidenced by a Mini-Mental State Examination (MMSE) score of more than 24 of 30\n3. Chinese Mandarin as the native language\n4. providing informed consent\n\nExclusion Criteria:\n\n1. pre-existing delirium assessed according to the Confusion Assessment Method (CAM)\n2. history of neurological or psychiatric disease\n3. impaired vision or auditory function which may effect the assessments\n4. unwillingness to participate in the study",{"count":430,"type":21},200,"Postoperative delirium is common in patients undergoing cardiovascular surgery and associated with poor outcomes. However the pathogenesis of postoperative delirium is poorly understood. Multichannel electroencephalogram is a recognized tool for identifying neurophysiologic states during anesthesia, sleep, and arousal. The aim of the current study is to evaluate the mechanisms and predictors of postoperative delirium in patients undergoing cardiovascular surgery using electroencephalogram.",[29],{"date":389,"type":34},{"date":435,"type":34},"2021-06-17",{"date":419,"type":21},{"name":421,"class":41},{"id":439,"slug":440,"hasResults":12,"nctId":441,"briefTitle":442,"officialTitle":443,"acronym":4,"eligibilityCriteria":444,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":445,"enrollmentInfo":446,"targetDuration":4,"studyType":85,"phases":4,"briefSummary":447,"conditions":448,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":414,"lastUpdatePostDateStruct":449,"startDateStruct":450,"completionDateStruct":452,"leadSponsor":453,"locationsCount":118},"100369544","perioperative-eeg-monitoring-and-emergence-delirium-in-children-100369544","NCT04091724","Perioperative EEG-Monitoring and Emergence Delirium in Children","Perioperative EEG-Monitoring and Emergence Delirium in Children: a Prospective Observational Study","Inclusion Criteria:\n\n1. male or female children aged under 16 years\n2. planned elective surgery\n3. informed consent by parents or legal guardians\n\nExclusion Criteria:\n\n1. history of neurological or psychiatric disease\n2. delayed development\n3. inability of the parents or legal guardians to speak or read Chinese\n4. participation in another prospective interventional clinical study during this study","16 Years",{"count":333,"type":21},"Emergence delirium is a significant problem, particularly in children. However the incidence, preventative strategies, and management of emergence delirium remain unclear. Multichannel electroencephalogram is a recognized tool for identifying neurophysiologic states during anesthesia, sleep, and arousal. The aim of the current study is to evaluate the mechanisms and predictors of emergence delirium in children under 16 years scheduled for elective surgery using electroencephalogram. The \"Pediatric Anesthesia Emergence Delirium Scores (PAED Score)\" (Sikich et al. 2004) is used to screen for the occurrence of emergence delirium in the post anesthesia care unit.",[29],{"date":389,"type":34},{"date":451,"type":34},"2019-12-02",{"date":419,"type":21},{"name":421,"class":41},{"id":455,"slug":456,"hasResults":12,"nctId":457,"briefTitle":458,"officialTitle":458,"acronym":459,"eligibilityCriteria":460,"healthyVolunteers":172,"sex":17,"minAge":82,"maxAge":461,"enrollmentInfo":462,"targetDuration":4,"studyType":22,"phases":464,"briefSummary":465,"conditions":466,"keywords":472,"overallStatus":108,"whyStopped":4,"lastUpdateSubmitDate":478,"lastUpdatePostDateStruct":479,"startDateStruct":481,"completionDateStruct":483,"leadSponsor":485,"locationsCount":4},"100614595","bedside-bike-early-mobilization-program-for-inpatients-100614595","NCT07281638","Bedside Bike Early Mobilization Program for Inpatients","BB-STEP","Inclusion Criteria:\n\n* Age 18 years or older\n* Admitted to participating hospital unit within 24 hours or less\n* Expected hospital stay of at least 3 days\n* Able to follow one-step commands\n* Anti-gravity leg strength\n* Informed consent obtained from patient or legally authorized representative\n\nExclusion Criteria:\n\n* Hemodynamic instability requiring vasopressor support with systolic blood pressure \\\u003C90 mmHg\n* Requiring fraction of inspired oxygen (FiO₂) \\>0.6 or positive end-expiratory pressure (PEEP) \\>8 cm H₂O\n* Uncontrolled cardiac arrhythmia\n* Open lower extremity wounds within the pedal arc area\n* Lower limb fracture requiring traction or immobilization\n* Active deep vein thrombosis (DVT) without therapeutic anticoagulation\n* Body mass index (BMI) \\>45 kg\u002Fm² (exceeds device reach limit)\n* Current pregnancy\n* Concurrent enrollment in another interventional clinical trial that would conflict with study procedures or outcomes","110 Years",{"count":463,"type":21},80,[24],"Hospital immobility leads to serious complications including muscle loss, weakness, delirium, pressure ulcers, and blood clots. Despite being medically stable, hospitalized patients spend over 90% of their time in bed due to staffing shortages, fall risks, and limited physical therapy availability. Within one week of admission, patients can lose approximately 2% of thigh muscle mass per day, and nearly half develop clinically significant hospital-acquired weakness.The Bedside Bike is a portable, low-resistance exercise device that clamps securely to hospital beds, allowing patients to perform leg and arm cycling exercises safely without leaving their bed. This study will evaluate whether hospitalized patients at Indiana University Health facilities can feasibly and safely use the Bedside Bike to maintain mobility during their hospital stay.This quality improvement study will enroll 80 adult inpatients expected to stay at least 3 days. All participants will receive the Bedside Bike in addition to usual care (standard physical therapy and medical treatment). The study will measure how often patients use the device, whether it is safe (tracking any device-related problems), and whether it may help improve outcomes such as hospital length of stay, functional mobility scores, discharge to home, and rates of hospital-acquired weakness. Participants will have functional assessments at admission and discharge, use the Bedside Bike throughout their hospitalization (targeting at least 15 minutes daily), and be followed for 60 days after discharge to track readmissions, falls, living arrangements, and mortality.",[467,468,29,469,470,471],"Immobility Syndrome","Deep Venous Thrombosis","Hospital Acquired Condition","Fall","Mobility Limitation",[473,474,475,476,477],"Immobility Harm","Hospital-Acquired Disability","Falls","Deconditioning","In-bed exercise","2026-03-24",{"date":480,"type":34},"2026-03-27",{"date":482,"type":21},"2026-07-05",{"date":484,"type":21},"2026-12-31",{"name":486,"class":41},"Indiana University",{"id":488,"slug":489,"hasResults":12,"nctId":490,"briefTitle":491,"officialTitle":491,"acronym":4,"eligibilityCriteria":492,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":493,"targetDuration":4,"studyType":22,"phases":494,"briefSummary":495,"conditions":496,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":478,"lastUpdatePostDateStruct":500,"startDateStruct":501,"completionDateStruct":503,"leadSponsor":504,"locationsCount":118},"100474683","early-phase-1-regional-nerve-blocks-to-improve-analgesia-and-recovery-in-older-adults-undergoing-spinal-fusion-100474683","NCT05461092","Regional Nerve Blocks to Improve Analgesia and Recovery in Older Adults Undergoing Spinal Fusion","Inclusion Criteria:\n\n* Are 65 or older\n* Indicated for lumbar spinal fusion of less than or equal to 3 levels\n* Undergoing elective surgery\n* no contraindications to local anesthetic or procedures\n* no severe cardiac or respiratory disease\n* no preexisting cognitive dysfunction\u002Fdementia\n\nExclusion Criteria:\n\n* 64 years old and younger\n* emergency treatment\n* pathologic fractures\n* seeking revision surgery\n* major liver or kidney dysfunction\n* coexisting hematological disorder or irreversible abnormal coagulation\n* patients with previous diagnosis of dementia or SLUMS score \\\u003C20\n* patient unable to communicate\u002Fcooperate\u002Flanguage barrier\n* BMI\\>40\n* allergy to study medications\n* opioid tolerant (oral opioid intake morphine equivalent =\\\u003C 60 mg\u002Fday)\n* other sources of chronic pain like fibromyalgia\n* patients with associated significant CNS or respiratory disease (home oxygen requirements)\n* incarcerated patients\n* psychiatric illnesses preoperative neurological deficits greater than one motor group, less than three out of five motor functions\n* pregnant or breast feeding",{"count":309,"type":21},[311],"This initial study is a feasibility study for implementing thoracolumbar interfascial plane, or TLIP, blocks in older adults undergoing spinal fusion. TLIP blocks are done by using anesthesia. In this case, it will be done to either side of the back where surgery will be performed. This has been shown to decrease pain the patients have post-operatively in previous research. In this study, the investigators will examine recruitment rates, completion of assessments, dropout rate, gather patient feedback, and identify barriers to performing TLIP. Further, this feasibility study will provide data to determine adequate sample size and refine methods and outcomes for a future randomized clinical trial. The ultimate goal is to perform a large, appropriately powered randomized control trial to determine the effect of TLIP blocks on pain, physical function and disability, opioid consumption, and delirium in older adult undergoing spinal fusion.",[29,497,498,499],"Pain, Back","Spinal Fusion","Thoracolumbar Interfascial Plane Block",{"date":480,"type":34},{"date":502,"type":34},"2024-01-01",{"date":484,"type":21},{"name":505,"class":41},"University of Iowa",{"id":507,"slug":508,"hasResults":12,"nctId":509,"briefTitle":510,"officialTitle":511,"acronym":4,"eligibilityCriteria":512,"healthyVolunteers":12,"sex":17,"minAge":82,"maxAge":513,"enrollmentInfo":514,"targetDuration":4,"studyType":22,"phases":516,"briefSummary":517,"conditions":518,"keywords":519,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":523,"lastUpdatePostDateStruct":524,"startDateStruct":525,"completionDateStruct":527,"leadSponsor":528,"locationsCount":118},"100479647","vr-interventions-to-reduce-the-prevalence-of-delirium-in-icu-patients-100479647","NCT05525702","VR Interventions to Reduce the Prevalence of Delirium in ICU Patients","Effects of Multi-model Virtual Reality Intervention Method to Reduce the Prevalence of Delirium in ICU Patients With Mechanical Ventilation","Inclusion Criteria\n\n* Mechanical ventilation duration is expected to be greater than 24 hours;\n* ICU stay duration is expected to be greater than 72 hours;\n* Age is 18 years or older, with no upper age limit;\n* Language: Chinese. Exclusion Criteria\n* Severe visual or auditory impairments (diplopia, low vision due to macular degeneration, retinopathy; severe hearing loss or deafness);\n* Cognitive and consciousness disturbances prior to ICU admission;\n* Severe motion sickness;\n* Head trauma or surgery that prevents the wearing of equipment;\n* A history of long-term use of antipsychotic and\u002For benzodiazepine medications.","90 Years",{"count":515,"type":21},102,[24],"The goal of this clinical trial is to learn the effect of Virtual Reality Family Support System (VRFS) on reducing delirium in ICU mechanically ventilated patients. The main question it aims to answer is:\n\n·Using VRFS for participant intervention, can it reduce the incidence of delirium and improve clinical outcomes?\n\nResearchers will investigate whether the implementation of VRFS can reduce the number of delirium days and improve clinical outcomes.\n\nParticipants will:\n\n* Receive the VRFS intervention until the endotracheal tube (ETT) is removed.\n* Have physiological data collected, including EEG, oxygen saturation levels, ECG, and blood pressure.\n* Keep a diary of delirium, dosage of sedative and analgesic drugs, the duration of mechanical ventilation, and ICU stays.",[29],[520,521,29,522],"ICU","Virtual Reality","family support","2026-03-23",{"date":480,"type":34},{"date":526,"type":34},"2023-12-18",{"date":484,"type":21},{"name":529,"class":41},"Peking Union Medical College Hospital",{"id":531,"slug":532,"hasResults":12,"nctId":533,"briefTitle":534,"officialTitle":535,"acronym":536,"eligibilityCriteria":537,"healthyVolunteers":12,"sex":17,"minAge":147,"maxAge":4,"enrollmentInfo":538,"targetDuration":4,"studyType":22,"phases":540,"briefSummary":541,"conditions":542,"keywords":552,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":555,"lastUpdatePostDateStruct":556,"startDateStruct":557,"completionDateStruct":559,"leadSponsor":561,"locationsCount":563},"100510689","evaluating-novel-healthcare-approaches-to-nurturing-and-caring-for-hospitalized-elders-100510689","NCT05929703","Evaluating Novel Healthcare Approaches to Nurturing and Caring for Hospitalized Elders","Evaluating Novel Healthcare Approaches to Nurturing and Caring for Hospitalized Elders (ENHANCE)","ENHANCE","Inclusion Criteria:\n\n* Provision of informed consent\n* At least 70 years of age\n* Anticipated length of hospital stay at least 72 hours\n* Family member or care partner available to be on-site in the hospital\n* At least one delirium risk factor (e.g., cognitive or functional impairment, dehydration, vision or hearing impairment)\n* Evaluable cognitive function at baseline (i.e., ability to complete baseline cognitive function assessment)\n\nExclusion Criteria:\n\n* Delirium on admission\n* Unable to communicate verbally (e.g., coma, mechanical ventilation)\n* Unable to participate fully in interventions (e.g., terminal condition, advanced dementia)\n* Staff safety concerns (e.g., violent behavior)\n* Cardiac or intracranial surgery (due to competing causes of delirium)",{"count":539,"type":21},1900,[24],"The goal of this clinical trial is to compare the Hospital Elder Life Program (HELP) with a family-augmented version of HELP (FAM-HELP), that includes family members and care partners, for the prevention of delirium in older patients during hospital admission. The main objectives of the trial are the following:\n\n1. To compare the effectiveness of FAM-HELP and HELP in reducing both the incidence of delirium and its severity.\n2. To compare the effectiveness of FAM-HELP and HELP in improving patient- and family-reported outcomes.\n3. To explore the implementation context, process, and outcomes of the FAM-HELP program in diverse hospital settings.",[29,543,544,545,546,547,548,549,550,551],"Neurocognitive Disorders","Mild Cognitive Impairment","Alzheimer Disease","Aging","Family Support","Family Members","Caregiver Burden","Implementation Science","Patient Satisfaction",[29,553,554,550],"Clinical Trial","Comparative Effectiveness Research","2026-03-20",{"date":478,"type":34},{"date":558,"type":34},"2023-12-04",{"date":560,"type":21},"2027-08",{"name":562,"class":41},"University of Michigan",7,{"id":565,"slug":566,"hasResults":12,"nctId":567,"briefTitle":568,"officialTitle":569,"acronym":570,"eligibilityCriteria":571,"healthyVolunteers":12,"sex":17,"minAge":82,"maxAge":4,"enrollmentInfo":572,"targetDuration":4,"studyType":22,"phases":573,"briefSummary":575,"conditions":576,"keywords":577,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":583,"lastUpdatePostDateStruct":584,"startDateStruct":585,"completionDateStruct":587,"leadSponsor":589,"locationsCount":118},"100494107","phase-2-melatonin-for-treatment-of-delirium-in-critically-ill-adult-patients-100494107","NCT05713877","Melatonin for Treatment of Delirium in Critically Ill Adult Patients","DELIRE-ICU: A Randomised Controlled Feasibility Trial of Melatonin vs Placebo in the Treatment of Delirium in the Intensive Care Unit","DELIRE-ICU","Inclusion Criteria:\n\n* Patients aged 18 years or older admitted to the intensive care unit;\n* Anticipated ICU stay \\> 48 hours;\n* ICDSC score greater than or equal to 4 for a maximum of 48 hours prior to randomization.\n\nExclusion Criteria:\n\n* Known allergy or hypersensitivity to melatonin or to ingredients in ORA-BLEND SF®;\n* Use of melatonin within 24 hours prior to randomization;\n* Presence of severe structural brain injury (intracranial hemorrhage or traumatic brain injury), severe major neurocognitive disorder, advanced neurodegenerative disease or hepatic encephalopathy;\n* Diagnosis of schizophrenia, bipolar affective disorder, psychotic depression, uremic encephalopathy or alcohol withdrawal;\n* Presence of active seizures, coma, aphasia or severe intellectual disability;\n* Limited short-term vital prognosis;\n* Diagnosis of delirium prior to ICU admission;\n* Pregnancy or breastfeeding;\n* Absolute contraindication to receive enteral medication;\n* Inability to understand or speak English or French;\n* Total blindness.",{"count":381,"type":21},[574],"PHASE2","The purpose of this study is to determine the feasibility of conducting a randomized controlled trial (RCT) with melatonin for treatment of delirium in critically ill adult patients. From a feasibility perspective, the investigators believe that the proposed design will achieve the minimum enrollment rate necessary to conduct a future RCT on a larger scale.",[29],[578,579,580,581,582,520],"Melatonin","Intensive care","Feasibility","Treatment","Critically ill","2026-03-19",{"date":523,"type":34},{"date":586,"type":34},"2023-02-01",{"date":588,"type":21},"2026-12-30",{"name":590,"class":41},"Ciusss de L'Est de l'Île de Montréal",{"id":592,"slug":593,"hasResults":12,"nctId":594,"briefTitle":595,"officialTitle":595,"acronym":4,"eligibilityCriteria":596,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":597,"targetDuration":4,"studyType":85,"phases":4,"briefSummary":599,"conditions":600,"keywords":605,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":609,"lastUpdatePostDateStruct":610,"startDateStruct":611,"completionDateStruct":613,"leadSponsor":615,"locationsCount":118},"100630499","quality-improvement-project-to-reduce-preoperative-fasting-times-before-elective-procedures-100630499","NCT07488468","Quality Improvement Project to Reduce Preoperative Fasting Times Before Elective Procedures","Inclusion Criteria:\n\n* All patients elective surgery or intervention requiring with anesthesiology care general anesthesia, regional anesthesia, sedation, or anesthesiology stand-by\n\nExclusion Criteria:\n\n* Already sedated, intubated, and mechanically ventilated patients",{"count":598,"type":21},1000,"This single-center quality improvement project evaluates preoperative fasting times before elective procedures requiring anesthesiology care. The project aims to reduce prolonged fasting for clear fluids by implementing a local standard operating procedure (SOP) allowing patients to drink clear liquids until being called to the operating room (\"drink until called\"), supported by staff education and fasting instruction cards. Fasting times and selected perioperative outcomes will be assessed before and after implementation.",[601,602,603,604,29],"Preoperative Fasting","Perioperative Patient Comfort \u002F Quality of Care","Postoperative Nausea and Vomiting (PONV)","Postoperative Pulmonary Complications",[606,607,608],"Preoperative fasting","clear liquids","quality improvement","2026-03-17",{"date":523,"type":34},{"date":612,"type":34},"2026-01-30",{"date":614,"type":21},"2026-07-30",{"name":616,"class":41},"University of Giessen",{"id":618,"slug":619,"hasResults":12,"nctId":620,"briefTitle":621,"officialTitle":622,"acronym":623,"eligibilityCriteria":624,"healthyVolunteers":12,"sex":17,"minAge":147,"maxAge":4,"enrollmentInfo":625,"targetDuration":4,"studyType":22,"phases":627,"briefSummary":628,"conditions":629,"keywords":633,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":641,"lastUpdatePostDateStruct":642,"startDateStruct":644,"completionDateStruct":646,"leadSponsor":648,"locationsCount":42},"100509588","researching-efficient-approaches-to-delirium-identification-sustaining-effective-translation-100509588","NCT05915377","Researching Efficient Approaches to Delirium Identification-Sustaining Effective Translation","READI-SET-GO:Researching Efficient Approaches to Delirium Identification-Sustaining Effective Translation to Create Gero Friendly Organizations","READI-SET-GO","Inclusion Criteria:\n\n* General medicine (hospitalist) service\n* Age 70 or older\n* Expected hospital length of stay of 3 or more days\n\nExclusion Criteria:\n\n* Inability to communicate adequately in English\n* Admitted for terminal care",{"count":626,"type":21},1050,[24],"The goal of this step-wedge trial is to test the implementation of daily nurse screening for delirium in routine care and its impact on outcomes and complications in hospitalized older adults admitted to 6 general medicine\u002Fsurgery units at 3 hospitals in Pennsylvania and Massachusetts.\n\nThe main question\\[s\\] it aims to answer are:\n\n* 1\\. To test the fidelity, accuracy, and durability of implementing daily nurse screening for delirium using the UB-CAM in routine care.\n* 2\\. To evaluate the impact of UB-CAM delirium screening on patient and care partner centered outcomes assessed at one month follow-up interviews 3. To evaluate the impact of UB-CAM screening on rates of delirium complications (falls, pressure injury, aspiration) and adverse delirium management (psychoactive medication use, restraint use).\n\nParticipants (patients) will be assessed for delirium on study days 1, 2 and 3 (or until hospital discharge) and will be asked basic demographics. These patients will be contacted by phone 1 month after enrollment to collect information about inpatient facility use and to administer the Delirium Burden Patient Scale.\n\nParticipants (care partners) will be interviewed at the patient's discharge to complete the Alzheimer's Disease-8 scale. These care partners will be contacted by phone 1 month after enrollment to complete the Delirium Burden Caregiver Scale and to complete a Qualitative Interview which includes questions about communication and collaboration.",[29,630,631,632],"Delirium in Old Age","Delirium With Dementia","Delirium Superimposed on Dementia",[29,634,635,636,637,638,639,640],"Confusion","Altered Mental Status","Acute Metabolic Encephalopathy","Implementation","Screening","Acute Care","Electronic Health Record","2026-02-18",{"date":643,"type":34},"2026-02-20",{"date":645,"type":34},"2024-04-03",{"date":647,"type":21},"2028-05",{"name":649,"class":41},"Penn State University",{"id":651,"slug":652,"hasResults":12,"nctId":653,"briefTitle":654,"officialTitle":655,"acronym":656,"eligibilityCriteria":657,"healthyVolunteers":12,"sex":17,"minAge":658,"maxAge":4,"enrollmentInfo":659,"targetDuration":4,"studyType":22,"phases":661,"briefSummary":662,"conditions":663,"keywords":668,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":186,"lastUpdatePostDateStruct":670,"startDateStruct":672,"completionDateStruct":674,"leadSponsor":676,"locationsCount":678},"100530297","behavioral-economic--staffing-strategies-in-the-icu-100530297","NCT06184945","Behavioral Economic & Staffing Strategies in the ICU","Behavioral Economic and Staffing Strategies To Increase Adoption of an Evidence Based Bundle in the Intensive Care Unit (BEST ICU): A Stepped Wedge Cluster Randomized Controlled Trial","BEST-ICU","Inclusion Criteria:\n\n* Age \\>19 years at time of ICU admission\n* Received invasive mechanical ventilation while in the ICU\n* Admitted to participating cluster ICU\n* ICU length of stay of at least 24 hours\n\nExclusion Criteria:\n\n* Patient who is admitted to the hospital who is already receiving chronic long-term mechanical ventilation from the home, assisted living, or long-term care setting\n* Prisoners","19 Years",{"count":660,"type":21},8100,[24],"The overarching goal of this study is to support the \"real world\" assessment of strategies used to foster adoption of several highly efficacious evidence-based practices in healthcare systems that provide care to critically ill adults with known health disparities. Investigators will specifically evaluate two discrete strategies grounded in behavioral economic and implementation science theory (i.e., real-time audit and feedback and registered nurse implementation facilitation) to increase adoption of the ABCDEF bundle in critically ill adults.",[550,29,664,665,666,667],"Critical Illness","Mechanical Ventilation Complication","ICU Acquired Weakness","Pain",[669],"ABCDEF bundle, delirium, intensive care, critical care, mechanical ventilation",{"date":671,"type":34},"2026-02-19",{"date":673,"type":34},"2024-07-01",{"date":675,"type":21},"2028-04",{"name":677,"class":41},"University of Nebraska",3]